Fujisue Koichiro, Ito Miwa, Matsuzawa Yasushi, Arima Yuichiro, Takashio Seiji, Sueta Daisuke, Araki Satoshi, Hanatani Shinsuke, Yamanaga Kenshi, Yamamoto Masahiro, Kaneko Shozo, Yamamoto Eiichiro, Matsushita Kenichi, Soejima Hirofumi, Tsujita Kenichi
Department of Cardiovascular Medicine, Graduate School of Medical Sciences, Kumamoto University Kumamoto Japan.
Miyazaki Medical Association Hospital Miyazaki Japan.
Circ Rep. 2024 Feb 17;6(3):55-63. doi: 10.1253/circrep.CR-23-0099. eCollection 2024 Mar 8.
Neither the efficacy nor safety of elobixibat has been investigated in the treatment of chronic constipation in patients with heart failure (HF). In this prospective, single-center, single-arm study elobixibat (10 mg/day) was administered for 12 weeks to 18 HF patients with chronic constipation defined according to the Rome IV criteria. Spontaneous bowel movement (SBM), stool consistency as measured by the Bristol Stool Form Scale, and degree of straining during defecation were recorded. In addition, biomarkers, blood pressure (BP) measured by ambulatory monitoring, and adverse events were assessed. Although there was no significant difference, the frequency of SBM increased by 2.0/week from baseline to Week 12. Both the degree of straining during defecation and low-density lipoprotein cholesterol (LDL-C) levels were significantly decreased at Week 12 (straining, -0.79 [95% confidence interval (CI), -1.40 to -0.17]; LDL-C, -10.4 mg/dL [95% CI, -17.9 to -2.9]). Although not significant, the difference in BP before and after defecation tended to decrease from baseline by approximately 10 mmHg at Week 12. Serious adverse events were not observed. Elobixibat reduced the degree of straining during defecation, and improved the lipid profile in HF patients with chronic constipation.
在心力衰竭（HF）患者慢性便秘治疗中，elobixibat的疗效和安全性均未得到研究。在这项前瞻性、单中心、单臂研究中，按照罗马IV标准定义的18例慢性便秘HF患者接受elobixibat（10毫克/天）治疗12周。记录自主排便（SBM）、用布里斯托大便形状量表测量的大便稠度以及排便时的用力程度。此外，评估生物标志物、通过动态监测测量的血压（BP）和不良事件。虽然没有显著差异，但从基线到第12周，SBM频率每周增加2.0次。在第12周时，排便时的用力程度和低密度脂蛋白胆固醇（LDL-C）水平均显著降低（用力程度，-0.79 [95%置信区间（CI），-1.40至-0.17]；LDL-C，-10.4毫克/分升 [95% CI，-17.9至-2.9]）。虽然不显著，但在第12周时，排便前后的血压差异较基线时趋于降低约10 mmHg。未观察到严重不良事件。Elobixibat降低了慢性便秘HF患者排便时的用力程度，并改善了血脂状况。
